ArticleInflammopharmacology2025
Impact of Psidium guajava bark extract on inflammatory biomarkers in Wistar rat models of inflammation.
Article in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation is a critical response of the immune system to assault by either injury or infection. When the infection becomes chronic, it culminates to many diseases, like cardiovascular disorders, arthritis and autoimmune conditions. Conventional anti-inflammatory drugs, often cause side effects when used for long. Psidium guajava L. is often used in folklore medicine to treat inflammatory disorders due to its rich phytochemical composition. The present study investigated the anti-inflammatory effects of P. guajava bark in inflamed rat models. Ethanol extracts of P. guajava bark were prepared and analyzed for phytochemical constituents. The animal models were grouped into six and induced with inflammation using carrageenan. Treated groups received varying doses of the extract for 14 days, while control groups received either standard anti-inflammatory drugs or no treatment. Inflammatory responses were assessed through paw oedema measurement, pro-inflammatory cytokine like tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) analysis, cyclooxygenase-2 activity (Cox-2), antioxidant enzyme activity like superoxide dismutase, catalase, and glutathione peroxidase (Gpx), white blood cell count, protease inhibition, and C-reactive protein (CRP) levels. Molecular docking was performed to evaluate the binding affinity of bioactive compounds with inflammatory target proteins. The phytochemical screening revealed high concentrations of flavonoids, terpenoids, phenolics, and alkaloids. The treatment groups showed a significant (p ≤ 0.05) reduction in paw oedema size, TNF-α, IL-6 and Cox-2 levels compared to the untreated group. The extract also normalized antioxidant enzyme activity and reduced oxidative stress. Additionally, protease inhibition and CRP levels were significantly lower in treated rats. Molecular docking studies confirmed strong interactions between P. guajava bark bioactive compounds and inflammatory markers. The findings suggest that P. guajava bark possesses potent anti-inflammatory properties, potentially making it a viable alternative to synthetic anti-inflammatory drugs.
Indexed as
Identifiers
41118029What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.